The Center for Advanced Genetic Screens

Cellecta is a contract research organization whose primary focus is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.

With 7 years of experience performing HT RNAi and peptide screens and 10 NIH grants for genetic screen technology development, Cellecta is at the forefront of the HT genetic screening revolution.

> Learn more about our contract research services or customized products

> Learn more about Cellecta

Validated shRNA Libraries

Validated Pooled Lentiviral shRNA Libraries  New

Cellecta, partnered with Agilent Technologies, the Roswell Park Cancer Institute, FHCRC, TSRI, and Illumina, has created one of the most advanced, effective, and reliable pooled shRNA library platforms available.

HT Sequencing Results

High-Throughput RNAi Screens with Pooled shRNA Libraries

We'll perform any or all steps, from RNAi screening to HT sequencing to data analysis. Cellecta specializes in negative screens (i.e. viability, apoptosis).

Custom shRNA Constructs

Custom Lentiviral shRNA Constructs  New

Validated or Non-validated custom shRNA constructs can be generated using either your vector or Cellecta's, with your choice of tet-regulation, antibiotic resistance, fluorescent marker, and promoters.

2010 Brochure

Cellecta 2010 BrochureDownload the company brochure for an overview of Cellecta's HT Genetic Screen services.

Recent News

May 27, 2010

Cellecta receives an NIH SBIR Phase I Grant award (1R43CA144511-01) for the "Isolation of Peptide Radioprotectors". (NIH grant)

Upcoming Events

August 3, 2010

President and CEO Alex Chenchik will give a talk at the Clark Center, S-363, at Stanford University, Tuesday, August 3rd, from 4-5 pm, announcing a new Genetic Screen Platform and the Discovery of Drug Targets in Cancer Cell Models. (presentation)